Scientists in the U.K. developing world’s first vaccine to prevent ovarian cancer
OvarianVax, in development at the University of Oxford, has just received up to £600,000 from Cancer Research U.K. to pursue the world’s first vaccine designed to prevent ovarian cancer before it begins. The idea is to train the immune system to recognize over 100 proteins found on early-stage ovarian cancer cells, then destroy those cells before they can spread. For women carrying BRCA gene mutations, who currently face the wrenching choice of preventive surgery that ends fertility and triggers early menopause, a vaccine could transform what’s possible. It’s still early days, with lab work and clinical trials ahead, but the project signals a real shift in cancer research: moving from treatment toward prevention, and giving high-risk women better options worldwide.









